Haleon plc (LON:HLN) Receives Average Recommendation of "Moderate Buy" from Brokerages

Key Points

• Six brokers give Haleon an average recommendation of "Moderate Buy" (four buys, one hold, one sell) with a 12‑month consensus target of GBX 407 and analyst targets ranging roughly GBX 335–512.
• Insider Brian McNamara sold 704,974 shares at GBX 368 (≈£2.59m); Haleon trades near GBX 344 with a 52‑week range of GBX 325.10–419.50 and a market cap of about £30.7bn (P/E ~18.6).

Haleon plc (LON:HLN - Get Free Report) has been given an average recommendation of "Moderate Buy" by the six ratings firms that are covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and four have given a buy recommendation to the company. The average twelve-month target price among analysts that have updated their coverage on the stock in the last year is GBX 407.

A number of equities analysts have recently issued reports on HLN shares. Berenberg Bank reiterated a "buy" rating and issued a GBX 512 price objective on shares of Haleon in a report on Thursday. Jefferies Financial Group reiterated a "buy" rating and issued a GBX 450 price objective on shares of Haleon in a report on Monday, March 30th. Deutsche Bank Aktiengesellschaft cut their price objective on Haleon from GBX 340 to GBX 335 and set a "buy" rating for the company in a report on Thursday, January 22nd. Finally, Royal Bank Of Canada reiterated a "sector perform" rating and issued a GBX 370 price objective on shares of Haleon in a report on Thursday.

Insider Activity

In other news, insider Brian McNamara sold 704,974 shares of the company's stock in a transaction dated Monday, March 23rd. The stock was sold at an average price of GBX 368, for a total value of £2,594,304.32. Insiders own 0.01% of the company's stock.

Haleon Price Performance

Haleon stock opened at GBX 344.10 on Friday. Haleon has a 52 week low of GBX 325.10 and a 52 week high of GBX 419.50. The business has a 50-day simple moving average of GBX 371.46 and a 200 day simple moving average of GBX 370.62. The company has a quick ratio of 0.93, a current ratio of 0.92 and a debt-to-equity ratio of 52.26. The stock has a market cap of £30.68 billion, a price-to-earnings ratio of 18.60, a PEG ratio of 1.49 and a beta of 0.33.

Haleon (LON:HLN - Get Free Report) last posted its earnings results on Thursday, February 26th. The company reported GBX 18.60 EPS for the quarter. Haleon had a return on equity of 6.43% and a net margin of 12.59%. On average, research analysts forecast that Haleon will post 19.5033282 earnings per share for the current fiscal year.

Haleon Company Profile

Haleon LSE / NYSE: HLN is a world-leading consumer health company, with a clear purpose to deliver better everyday health with humanity. In July 2022, it listed as an independent company on the London and New York Stock Exchanges. Haleon's product portfolio spans six major categories - Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Its long-standing brands - such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren - are built on trusted science, innovation and deep human understanding.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.